FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896445089> ?p ?o ?g. }

• W2896445089 endingPage "345" @default.
• W2896445089 startingPage "337" @default.
• W2896445089 abstract "Breast and ovarian cancer are common malignancies among older adults, causing significant morbidity and mortality. Although most cases of breast and ovarian cancer are sporadic, a significant proportion is caused by mutations in cancer susceptibility genes, most often breast cancer susceptibility genes (BRCA) 1 and 2. Furthermore, some breast and ovarian tumors are phenotypically similar to those with BRCA mutations, a phenomenon known as “BRCAness”. BRCA mutations and “BRCAness” lead to defects in DNA repair, which may be a target for therapeutic agents such as Poly ADP-Ribose Polymerase (PARP) inhibitors. PARP inhibitors are novel medications which lead to double-strand breaks resulting in cell death due to synthetic lethality, and which have been shown to be effective in patients with advanced breast and ovarian cancers with or without BRCA mutations. Three different PARP inhibitors (olaparib, niraparib, and rucaparib) have been approved for the treatment of ovarian cancer and one (olaparib) for breast cancer harboring BRCA mutations. Here, we review the currently available evidence regarding the use of PARP inhibitors for the treatment of patients with breast and ovarian cancer, with a particular focus on the inclusion of older adults in clinical trials of these therapies. Additionally, we provide an overview of currently ongoing studies of PARP inhibitors in breast and ovarian cancer, and include recommendations for increasing the evidence-base for using these medications among older patients." @default.
• W2896445089 created "2018-10-26" @default.
• W2896445089 creator A5024632773 @default.
• W2896445089 creator A5028963681 @default.
• W2896445089 creator A5032002590 @default.
• W2896445089 creator A5032960604 @default.
• W2896445089 creator A5040291379 @default.
• W2896445089 creator A5045867757 @default.
• W2896445089 creator A5052784675 @default.
• W2896445089 creator A5065447416 @default.
• W2896445089 creator A5080292051 @default.
• W2896445089 date "2019-03-01" @default.
• W2896445089 modified "2023-09-30" @default.
• W2896445089 title "PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper" @default.
• W2896445089 cites W1523531555 @default.
• W2896445089 cites W1968585700 @default.
• W2896445089 cites W1973123264 @default.
• W2896445089 cites W1984919526 @default.
• W2896445089 cites W1987760772 @default.
• W2896445089 cites W1989006164 @default.
• W2896445089 cites W1991020867 @default.
• W2896445089 cites W1991034469 @default.
• W2896445089 cites W2004402393 @default.
• W2896445089 cites W2013923593 @default.
• W2896445089 cites W2017289276 @default.
• W2896445089 cites W2034269086 @default.
• W2896445089 cites W2045805729 @default.
• W2896445089 cites W2049553585 @default.
• W2896445089 cites W2062946371 @default.
• W2896445089 cites W2065283592 @default.
• W2896445089 cites W2070882208 @default.
• W2896445089 cites W2076295498 @default.
• W2896445089 cites W2094646262 @default.
• W2896445089 cites W2104885590 @default.
• W2896445089 cites W2105496345 @default.
• W2896445089 cites W2107243894 @default.
• W2896445089 cites W2110017381 @default.
• W2896445089 cites W2110137106 @default.
• W2896445089 cites W2116398119 @default.
• W2896445089 cites W2117692326 @default.
• W2896445089 cites W2118498634 @default.
• W2896445089 cites W2121977448 @default.
• W2896445089 cites W2123696077 @default.
• W2896445089 cites W2128746885 @default.
• W2896445089 cites W2132266605 @default.
• W2896445089 cites W2140289804 @default.
• W2896445089 cites W2145188374 @default.
• W2896445089 cites W2145568247 @default.
• W2896445089 cites W2149386818 @default.
• W2896445089 cites W2151213561 @default.
• W2896445089 cites W2153294383 @default.
• W2896445089 cites W2154008407 @default.
• W2896445089 cites W2154221980 @default.
• W2896445089 cites W2160466424 @default.
• W2896445089 cites W2162956417 @default.
• W2896445089 cites W2170719826 @default.
• W2896445089 cites W2171972386 @default.
• W2896445089 cites W2180500040 @default.
• W2896445089 cites W2199466904 @default.
• W2896445089 cites W2281930375 @default.
• W2896445089 cites W2295085830 @default.
• W2896445089 cites W2367214440 @default.
• W2896445089 cites W2396892895 @default.
• W2896445089 cites W2463058287 @default.
• W2896445089 cites W2469627334 @default.
• W2896445089 cites W2474664935 @default.
• W2896445089 cites W2508311761 @default.
• W2896445089 cites W2519148856 @default.
• W2896445089 cites W2528228811 @default.
• W2896445089 cites W2550229146 @default.
• W2896445089 cites W2557666746 @default.
• W2896445089 cites W2561042858 @default.
• W2896445089 cites W2587333476 @default.
• W2896445089 cites W2600086771 @default.
• W2896445089 cites W2602189257 @default.
• W2896445089 cites W2610368132 @default.
• W2896445089 cites W2621271973 @default.
• W2896445089 cites W2673776326 @default.
• W2896445089 cites W2733049975 @default.
• W2896445089 cites W2737389832 @default.
• W2896445089 cites W2740632734 @default.
• W2896445089 cites W2751912349 @default.
• W2896445089 cites W2754327139 @default.
• W2896445089 cites W2756272086 @default.
• W2896445089 cites W2763602017 @default.
• W2896445089 cites W2764124094 @default.
• W2896445089 cites W2788106879 @default.
• W2896445089 cites W2794458938 @default.
• W2896445089 cites W2801520211 @default.
• W2896445089 cites W2801956643 @default.
• W2896445089 cites W3093265161 @default.
• W2896445089 cites W4211006558 @default.
• W2896445089 cites W4231014485 @default.
• W2896445089 cites W4243841665 @default.
• W2896445089 cites W594329094 @default.
• W2896445089 cites W95552543 @default.
• W2896445089 doi "https://doi.org/10.1016/j.jgo.2018.10.008" @default.
• W2896445089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30333088" @default.

• next